Literature DB >> 2878985

Correlation between polymorphic DNA haplotypes at phenylalanine hydroxylase locus and clinical phenotypes of phenylketonuria.

F Güttler, F D Ledley, A S Lidsky, A G DiLella, S E Sullivan, S L Woo.   

Abstract

Eight polymorphic sites for seven restriction endonucleases have been reported at the human phenylalanine hydroxylase locus. The composite profile of the presence or absence for each of the eight polymorphic sites within an allele defines the haplotype of the corresponding allele. Twelve such haplotypes associated with normal and mutant phenylalanine hydroxylase alleles have been identified in 33 Danish families with children with phenylketonuria. Of the 66 mutant alleles analyzed, 59 (89%) were associated with only four haplotypes. The identification of individual phenylalanine hydroxylase alleles by haplotype analysis enables correlation of the hyperphenylalaninemic phenotypes of the patients with their genotypes. Patients who were either homozygous or heterozygous for the mutant alleles of haplotypes 2 and 3 had a severe clinical course. Patients who had a mutant allele of either haplotype 1 or 4 usually had a less severe clinical phenotype. The recent demonstration that the mutation responsible for classic phenylketonuria associated with haplotype 3 is not present in mutant alleles of other haplotypes provides unambiguous evidence that there are multiple mutations in the phenylalanine hydroxylase gene and supports the hypothesis that different combinations of mutant alleles may be responsible for the clinical diversity of phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2878985     DOI: 10.1016/s0022-3476(87)80290-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  32 in total

Review 1.  Heterogeneity of phenylketonuria at the clinical, protein and DNA levels.

Authors:  R G Cotton
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  Study design and description of patients.

Authors:  P Lutz; H Schmidt; U Batzler
Journal:  Eur J Pediatr       Date:  1990       Impact factor: 3.183

3.  Phenylketonuria in Italy: distinct distribution pattern of three mutations of the phenylalanine hydroxylase gene.

Authors:  V Guzzetta; G Bonapace; I Dianzani; G Parenti; M Lecora; S Giannattasio; D Concolino; P Strisciuglio; G Sebastio; G Andria
Journal:  J Inherit Metab Dis       Date:  1997-09       Impact factor: 4.982

4.  Molecular heterogeneity at the phenylalanine hydroxylase locus in the population of the south-west of England.

Authors:  L A Tyfield; M J Osborn; J B Holton
Journal:  J Med Genet       Date:  1991-04       Impact factor: 6.318

5.  Clinical and molecular heterogeneity of phenylalanine hydroxylase deficiencies in France.

Authors:  F Rey; M Berthelon; C Caillaud; S Lyonnet; V Abadie; F Blandin-Savoja; J Feingold; J M Saudubray; J Frézal; A Munnich
Journal:  Am J Hum Genet       Date:  1988-12       Impact factor: 11.025

Review 6.  Molecular genetics of phenylketonuria and its implications.

Authors:  H L Levy
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

7.  Identification of the haplotype pattern associated with the mutant PKU allele in the Gypsy population of Wales.

Authors:  L A Tyfield; A L Meredith; M J Osborn; P S Harper
Journal:  J Med Genet       Date:  1989-08       Impact factor: 6.318

8.  GT to AT transition at a splice donor site causes skipping of the preceding exon in phenylketonuria.

Authors:  J Marvit; A G DiLella; K Brayton; F D Ledley; K J Robson; S L Woo
Journal:  Nucleic Acids Res       Date:  1987-07-24       Impact factor: 16.971

Review 9.  The influence of mutations of enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency.

Authors:  F Güttler; P Guldberg
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

10.  Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age. The Paris Study.

Authors:  F Rey; V Abadie; F Plainguet; J Rey
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.